Abstract:Background: Excessive endogenous glucose production is a major contributing factor for fasting hyperglycemia in diabetes. Results: FoxO6 deficiency attenuates hepatic gluconeogenesis and protects against fat-induced glucose disorder in mice. Conclusion: FoxO6 plays a significant role in regulating gluconeogenesis in the liver. Significance: FoxO6 is a potential therapeutic target for improving glucose metabolism in diabetes. Excessive endogenous glucose production contributes to fasting hyperglycemia in diabetes. FoxO6 is a distinct member of the FoxO subfamily. To elucidate the role of FoxO6 in hepatic gluconeogenesis and assess its contribution to the pathogenesis of fasting hyperglycemia in diabetes, we generated FoxO6 knock-out (FoxO6-KO) mice followed by determining the effect of FoxO6 loss-of-function on hepatic gluconeogenesis under physiological and pathological conditions. FoxO6 depletion attenuated hepatic gluconeogenesis and lowered fasting glycemia in FoxO6-KO mice. FoxO6-deficient primary hepatocytes were associated with reduced capacities to produce glucose in response to glucagon. When fed a high fat diet, FoxO6-KO mice exhibited significantly enhanced glucose tolerance and reduced blood glucose levels accompanied by improved insulin sensitivity. These effects correlated with attenuated hepatic gluconeogenesis in FoxO6-KO mice. In contrast, wild-type littermates developed fat-induced glucose intolerance with a concomitant induction of fasting hyperinsulinemia and hyperglycemia. Furthermore, FoxO6-KO mice displayed significantly diminished macrophage infiltration into liver and adipose tissues, correlating with the reduction of macrophage expression of C-C chemokine receptor 2 (CCR2), a factor that is critical for regulating macrophage recruitment in peripheral tissues. Our data indicate that FoxO6 depletion protected against diet-induced glucose intolerance and insulin resistance by attenuating hepatic gluconeogenesis and curbing macrophage infiltration in liver and adipose tissues in mice.

FoxO6 in glucose metabolism (FoxO6).

FoxO6 Integrates Insulin Signaling with Gluconeogenesis in the Liver.

FoxO integration of insulin signaling with glucose and lipid metabolism.

Forkhead Box O6 (foxo6) Depletion Attenuates Hepatic Gluconeogenesis and Protects Against Fat-induced Glucose Disorder in Mice.

FoxO6 Integrates Insulin Signaling with MTP for Regulating VLDL Production in the Liver.

FoxO 6 in glucose metabolism FoxO 6 Depletion Attenuates Hepatic Gluconeogenesis and Protects Against Fat-Induced Glucose Disorder in Mice

SCP4 Promotes Gluconeogenesis through FoxO1/3a Dephosphorylation.

Nuclear Transcription Factor Foxo1 and Glucose,lipid Metabolism

Aberrant Forkhead Box O1 Function is Associated with Impaired Hepatic Metabolism

FoxO1 Links Hepatic Insulin Action to Endoplasmic Reticulum Stress

Endoplasmic reticulum stress induces hepatic steatosis through interaction between PPARα and FoxO6 in vivo and in vitro

Regulation of FoxOs Transcription Factors on Body Metabolism

Novel Mechanism of Foxo1 Phosphorylation in Glucagon Signaling in Control of Glucose Homeostasis

A Mutant Allele Encoding DNA Binding–Deficient FoxO1 Differentially Regulates Hepatic Glucose and Lipid Metabolism

Phosphorylation of Forkhead Protein FoxO1 at S253 Regulates Glucose Homeostasis in Mice.

Forkhead Box P1 (FOXP1) Transcription Factor Regulates Hepatic Glucose Homeostasis

Differential roles of FOXO transcription factors on insulin action in brown and white adipose tissue

Foxo1-Ser253 Phosphorylation Regulates Glucose Homeostasis in Mice

A Novel Mechanism by Foxo1 Phosphorylation Mediates Glucagon Signaling in Control of Glucose Homeostasis

FoxO1 Plays an Important Role in Regulating Β-Cell Compensation for Insulin Resistance in Male Mice.

An insulin-independent mechanism for transcriptional regulation of Foxo1 in type 2 diabetic mice